Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data

May 2025 in “ Frontiers in Immunology ”

Yutong Sun, Qian Li, Yanli Zhang, Yaling Liu

Janus kinase inhibitors alopecia areata JAK inhibitors autoimmune disease inflammatory hair loss signal transducer and activator of transcription pathway T-cell-mediated inflammatory cytokine pathways hair follicle stem cell activation AA

Studysummary This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.

Janus kinase (JAK) inhibitors have shown promising results in treating alopecia areata (AA), an autoimmune disease causing inflammatory hair loss. These inhibitors work by blocking the signal transducer and activator of transcription pathway, thereby interfering with T-cell-mediated inflammatory cytokine pathways and promoting hair follicle stem cell activation. Clinical data indicate that JAK inhibitors are effective and safe for AA treatment, with minimal serious side effects. The review discusses the mechanism of action and evaluates the efficacy and safety of various JAK inhibitors in managing AA.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

48 / 48 results

research Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021

February 2025 in “PubMed”

This study found that although the global incidence of alopecia areata has risen since 1990, age-standardized rates have slightly decreased, with significant comorbidity associations varying by region.

research Oral Abrocitinib for Treatment of Refractory Alopecia Areata: A Retrospective Study

4 citations , October 2024 in “Journal of the American Academy of Dermatology”

Abrocitinib may help treat alopecia areata effectively with mild side effects.

research Sustained Hair Regrowth With Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Trial

7 citations , October 2024 in “Journal of the American Academy of Dermatology”

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

research Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib is generally safe for treating alopecia areata.

research Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

research Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Tofacitinib for Treating Alopecia Areata

July 2024 in “Journal of Controlled Release”

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

research Deciphering the Complex Immunopathogenesis of Alopecia Areata

45 citations , May 2024 in “International Journal of Molecular Sciences”

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

research Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis

20 citations , January 2024 in “Journal of the European Academy of Dermatology and Venereology”

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

research Gut Microbiome, Metabolome and Alopecia Areata

2 citations , November 2023 in “Frontiers in microbiology”

This review suggests that the gut microbiome and metabolome may play a significant role in alopecia areata and emphasizes the potential of targeting these factors for improved prevention, diagnosis, and treatment strategies for this skin condition.

research Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program

4 citations , November 2023 in “SKIN The Journal of Cutaneous Medicine”

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

research Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study

2 citations , November 2023 in “Acta dermato-venereologica”

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

research Ritlecitinib: First Approval

84 citations , August 2023 in “Drugs”

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

research Baricitinib: A Review in Severe Alopecia Areata

1 citations , June 2023 in “American Journal of Clinical Dermatology”

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

research Baricitinib for the Treatment of Alopecia Areata

6 citations , May 2023 in “Drugs”

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Treatment of Moderate-to-Severe Alopecia Areata in Pre-Adolescent Children with Baricitinib

17 citations , April 2023 in “British Journal of Dermatology”

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review

2 citations , April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

research Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

75 citations , March 2023 in “JAMA Dermatology”

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , February 2023 in “American Journal of Clinical Dermatology”

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study

6 citations , February 2023 in “Journal of the American Academy of Dermatology”

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

research Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients

January 2023 in “Journal of The American Academy of Dermatology”

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

12 citations , December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.

research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib

11 citations , February 2022 in “JAAD case reports”

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

research Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review

4 citations , January 2022 in “Dermatologic Therapy”

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial

20 citations , December 2021 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations , December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata

42 citations , April 2021 in “JCI insight”

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells

16 citations , July 2020 in “International Journal of Molecular Sciences”

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

research Frontiers in Alopecia Areata Pathobiology Research

55 citations , October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.

research Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis

12 citations , August 2019 in “Dermatitis”

This case report describes a 42-year-old woman with atopic dermatitis, whose alopecia areata reactivated rapidly after starting dupilumab, possibly indicating an unrecognized adverse effect in AD patients.

research Tofacitinib Therapy for Children with Severe Alopecia Areata

39 citations , January 2019 in “Journal of the American Academy of Dermatology”

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

research JAK Inhibitors and Alopecia Areata

56 citations , January 2019 in “Lancet”

This review discusses the emerging use of JAK inhibitors in alopecia areata treatment and reports no new clinical results; it highlights hair regrowth despite symptom recurrence after stopping therapy.

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , December 2018 in “Journal of autoimmunity”

This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.

research Ruxolitinib for the Treatment of Severe Alopecia Areata

37 citations , September 2018 in “Journal of the American Academy of Dermatology”

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children

40 citations , September 2018 in “Journal of the American Academy of Dermatology”

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

research Alopecia Areata: A Review of Disease Pathogenesis

191 citations , May 2018 in “British journal of dermatology/British journal of dermatology, Supplement”

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

research Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis

49 citations , May 2018 in “Journal of the American Academy of Dermatology”

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

$Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series$

research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

44 citations , October 2017 in “Journal of the American Academy of Dermatology”

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.